Plus Therapeutics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/25/2026)
| Balance Sheet | Total Assets | 16,325,000.00 | ROE | – |
| Balance Sheet | Total Equity | 3,996,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -67,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -20,842,000.00 | – | – |
| Cashflow | Operating Cash Flow | -20,775,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -181.25 | Div. Yield | – |
| Income | Net Income | -22,386,000.00 | P/E | – |
| Income | Shares Outstanding | 124,800.00 | P/B | – |
| Income | Total Revenue | 5,213,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Cytori Therapeutics, Inc. develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company´s clinical pipeline is for cardiovascular disease. The Company´s products include Celbrush, Puregraft, and Cytori LipoBank. The Celbrush is available in the 10 milliliter and 3 milliliter sizes and is used in conjunction with a Soft-Ject Syringe in the corresponding size. The Puregraft System is developed for autologous fat grafting and aesthetic body contouring. The Puregraft System is available in two sizes: 250 milliliter, which processes 50-250 milliliter of tissue, and 850 milliliter, which processes 200-850 milliliter of tissue. The Cytori LipoBank is a GTP-compliant cryopreservation system that offers a long-term storage option for viable adipose tissue after a single liposuction.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.cytori.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more